Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell...
Understanding relations between MRD and CAR T-Cell therapy
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body...
Mesenchymal stem cell therapy in neurological disorders
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven’t always worked, which has led...
Orphan drug designation is given by FDA to CART T-Cell Therapy A2B530 for the treatment of colorectal cancer
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer...
Iovance’s Amtagvi is approved by USFDA as first T-cell therapy for a solid tumor
Iovance Biotherapeutics’ first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are...
Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth...
Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell...
Lifileucel is approved by the USFDA for unresectable or metastatic melanoma
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with...
Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer...
Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic...
Erdafitinib is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have...
Pembrolizumab with chemoradiotherapy is approved by the USFDA for FIGO 2014 Stage III-IVA cervical cancer
The Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in combination with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer on January...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.